Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Carolina Valeria Mahuad, Maria de los Ángeles Vicente Repáraz, Marta E. Zerga, María Florencia Aizpurúa, Claudia Casali, Gonzalo Garate
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2016-06-01
coleção:	Rare Tumors
Assuntos:	Lymphoma large-cell anaplastic anaplastic lymphoma kinase crizotinib
Acesso em linha:	http://www.pagepress.org/journals/index.php/rt/article/view/6266
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!